

UCSF

UC San Francisco Previously Published Works

Title

Sex differences in interacting genetic and functional connectivity biomarkers in Alzheimer's disease

Permalink

<https://escholarship.org/uc/item/00n6d2xw>

Journal

GeroScience, 46(6)

ISSN

2509-2715

Authors

Williamson, Jordan N

James, Shirley A

Mullen, Sean P

et al.

Publication Date

2024-12-01

DOI

10.1007/s11357-024-01151-x

Peer reviewed



Sex differences in interacting genetic and functional connectivity biomarkers in Alzheimer’s disease

Jordan N. Williamson · Shirley A. James · Sean P. Mullen · Bradley P. Sutton · Tracey Wszalek · Beni Mulyana · Peter Mukli · Andriy Yabluchanskiy · Alzheimer’s Disease Neuroimaging Initiative Consortium · Yuan Yang

Received: 26 December 2023 / Accepted: 1 April 2024 / Published online: 10 April 2024
© The Author(s), under exclusive licence to American Aging Association 2024

Abstract As of 2023, it is estimated that 6.7 million individuals in the United States live with Alzheimer’s disease (AD). Prior research indicates that AD disproportionality affects females; females have a greater incidence rate, perform worse on a variety of neuropsychological tasks, and have greater total brain atrophy. Recent research shows that hippocampal functional connectivity differs by sex and may be related to the observed sex differences in AD, and apolipoprotein E (ApoE) $\epsilon 4$ carriers have

reduced hippocampal functional connectivity. The purpose of this study was to determine if the ApoE genotype plays a role in the observed sex differences in hippocampal functional connectivity in Alzheimer’s disease. The resting state fMRI and T2 MRI of individuals with AD ($n=30$, female=15) and cognitively normal individuals ($n=30$, female=15) from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were analyzed using the functional connectivity toolbox (CONN). Our results demonstrated intrahippocampal functional connectivity differed between those without an $\epsilon 4$ allele and those with at least one $\epsilon 4$ allele in each group. Additionally, intrahippocampal functional connectivity differed only by sex when Alzheimer’s participants had at least one $\epsilon 4$ allele. These results improve our current understanding of the role of the interacting relationship between sex, ApoE genotype, and hippocampal function in AD. Understanding these biomarkers may aid

The data used in the preparation of this article were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database (adni.loni.usc.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in the analysis or writing of this report. A complete listing of ADNI investigators can be found at http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf and in the “Acknowledgements” section.

J. N. Williamson · B. P. Sutton · B. Mulyana · Y. Yang (✉)
Grainger College of Engineering, Department of Bioengineering, University of Illinois Urbana-Champaign, Urbana, IL, USA
e-mail: yuan@illinois.edu

J. N. Williamson
e-mail: Jordan36@illinois.edu

B. P. Sutton
e-mail: bsutton@illinois.edu

B. Mulyana
e-mail: bmulyana1111@gmail.com

S. A. James
Hudson College of Public Health, University of Oklahoma Health Science Center, Oklahoma City, OK, USA
e-mail: shirley-james@ouhsc.edu

S. P. Mullen · B. P. Sutton · T. Wszalek · Y. Yang
Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, IL, USA
e-mail: spmullen@illinois.edu

T. Wszalek
e-mail: traceyws@illinois.edu

in the development of sex-specific interventions for improved AD treatment.

Keywords Alzheimer's disease (AD) · Sex difference · Apolipoprotein E · Functional connectivity

Introduction

The 2023 estimate of Americans over the age of 65 living with Alzheimer's disease (AD) is 6.7 million [1]. AD is currently the fifth leading cause of death for those older than 65 years living in the United States [2, 3]. Alzheimer's disease disrupts communication, metabolism, and repair of neurons and their networks [4]. It is characterized by abnormal levels of amyloid plaques, neurofibrillary tangles, chronic inflammation, and vascular dysfunction [4, 5]. Individuals with AD develop memory impairments that severely impact daily life. AD disproportionately affects females, as the prevalence of AD is two-thirds higher in women than men [2, 3]. Additionally, compared to males with AD, females perform poorer on a variety of neuropsychological tasks and have greater total brain atrophy and temporal lobe degeneration [6–8]. Theories for the sex-biased differences in AD include sex-specific developmental factors such as hormonal differences and menopause and hypertensive disorders of pregnancy [9–12]. Additionally, differences have been linked to sex differences in known risk factors, such as age, depression, education level, and sleep [11, 13]. The independent contributions of cognitive and genetic risk factors for AD have received considerable attention; however, their interactions are less known.

S. P. Mullen
Department of Kinesiology & Community Health,
University of Illinois Urbana-Champaign, Urbana, IL,
USA

S. P. Mullen
Informatics Programs, University of Illinois Urbana-
Champaign, Urbana, IL, USA

S. P. Mullen
Center for Social & Behavioral Sciences, University
of Illinois Urbana-Champaign, Urbana, IL, USA

Previous work has shown a possible interaction between sex and a known genetic risk factor for AD, the apolipoprotein E $\epsilon 4$ allele (ApoE-4). In humans, ApoE exists in three different isoforms, $\epsilon 2$, $\epsilon 3$, and $\epsilon 4$. The expression of ApoE isoforms and AD is multifactorial; a recent finding showed that an $\epsilon 2$ allele robustly decreases late-onset AD, whereas the expression of one $\epsilon 4$ allele increases the risk of developing AD, and the expression of two $\epsilon 4$ alleles increases the risk 9–15-fold [14–16]. The ApoE-4 is expressed in more than half of AD patients [17]. The presence of the ApoE-4 is known to cause numerous structural and functional brain changes associated with AD, including amyloid- β mechanisms, synaptic plasticity, cholesterol homeostasis, neurovascular function, and neuroinflammation [18–20]. Functional connectivity (FC) studies using electroencephalography (EEG) have shown that ApoE-4 is associated with functional network disruptions [21, 22]. However, the ApoE-4 role in the sex differences of AD is still being debated as the current results are inconsistent [18, 23–25].

Recently, research has revealed that hippocampal FC may be a biomarker and contributing factor in sex differences. Hippocampal atrophy has been found to be significantly faster and affect the progression of AD only in females [26, 27]. Additionally, previous studies have shown that females with AD have overall weaker hippocampal FC compared to males [28–31]. Further, previous work by Heise et. al has shown that in cognitively normal (CN)

P. Mukli · A. Yabluchanskiy
Vascular Cognitive Impairment and Neurodegeneration
Program, Oklahoma Center for Geroscience and Healthy
Brain Aging, Department of Neurosurgery, University
of Oklahoma Health Sciences Center, Oklahoma City, OK,
USA
e-mail: peter-mukli@ouhsc.edu

A. Yabluchanskiy
e-mail: andriy-yabluchanskiy@ouhsc.edu

Y. Yang
Clinical Imaging Research Center, Stephenson Family
Clinical Research Institute, Carle Foundation Hospital,
Urbana, IL, USA

Y. Yang
Department of Physical Therapy and Human Movement
Sciences, Northwestern University, Chicago, IL, USA

females, ApoE-4 carriers have reduced hippocampal FC to the precuneus and posterior cingulate cortex [32]. The purpose of this study was to build upon this prior research and determine if the ApoE genotype plays a role in the observed sex differences in functional connectivity of the hippocampus.

Methods

Data source

The data for this study were extracted from the ADNI [33], which is a publicly accessible dataset available at <http://adni.loni.usc.edu>. Launched in 2003, ADNI is a longitudinal, multi-site, cohort study, led by Principal Investigator Michael W. Weiner, MD. The original study, ADNI-1, has been extended three times, and the database contains subject data from ADNI-1, ADNI-GO, ADNI-2, and ADNI-3. The overall goal of the studies was to evaluate whether serial magnetic resonance imaging (MRI), positron emission tomography (PET), other biological markers, and clinical and neuropsychological assessment can be combined to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). For up-to-date information, see www.adni-info.org.

Participant selection

The data were filtered for participants with AD. Participant selection was limited to those with data collected from resting-state functional magnetic resonance imaging (rs-fMRI) and 3-Tesla T2 magnetic resonance imaging. Additionally, the data had to include the ApoE genotype. To maximize the sample size, participants were selected from any visit to ADNI-GO, ADNI-2, and ADNI-3. These cohorts used the same protocol to collect resting state data. A Philips system was used to collect straight axial rs-fMRI; the participants had their eyes open for the entire scan with their heads positioned on the mid-sagittal slice from the tri-planar scout. This process was repeated for

Table 1 Participant genotypes (AD, Alzheimer's disease; CN, cognitively normal)

Genotype	$\epsilon 2\epsilon 3$	$\epsilon 2\epsilon 4$	$\epsilon 3\epsilon 3$	$\epsilon 3\epsilon 4$	$\epsilon 4\epsilon 4$
AD female	0	0	3	9	3
AD male	2	0	3	6	4
CN female	2	1	6	5	1
CN male	1	0	9	5	0

cognitively normal (CN) individuals. Filtering the data resulted in a total of 17 AD females, 15 AD males, 28 CN females, and 22 CN males. To balance the number in each group, 15 of each group were computer randomly selected. Averages and standard deviation of available participant demographics of participants are provided in Table 1.

Analysis of functional connectivity

The participant's original rs-fMRI and MRI images (NiFTI format) were imported into the NITRC Functional Connectivity Toolbox (CONN) version 20b [34]. CONN utilizes SPM12 (Wellcome Department of Cognitive Neurology, UK) and MATLAB R2020a (MathWorks, Natick, MA, USA) in its processes and by default a combination of the Harvard–Oxford atlas (HOA distributed with FSL <http://www.fmrib.ox.ac.uk/fsl/>) [35–37] and the Automated Anatomical Labeling (AAL) atlas [38].

The images were processed through the default functional and structural preprocessing pipeline as detailed by Nieto-Castanon [39]. This included realignment, slice timing correction, coregistration/normalization, segmentation, outlier detection, and smoothing. Additionally, this step extracted the blood-oxygen-level dependent (BOLD) time series from the regions of interest (ROIs) (using the Harvard–Oxford cortical regions) and at the voxels. Next, the images were denoised to remove confounding effects from the BOLD signal through linear regression and band-pass filtering. This removes unwanted motion, physiological, and other artifactual effects from the BOLD signal before computed connectivity measures. The system used a combination of aCompCor (White and CSF ROIs, five components each), scrubbing (as many

regressors as identified invalid scans), motion regression (12 regressors: 6 motion parameters + 6 first-order temporal derivatives), and filtering. A quality assurance check was made after the denoising to ensure normalization and that there were no visible artifacts in the data.

A seed-to-voxel analysis was conducted for each participant. This analysis created a seed-based connectivity (SBC) map between the ROI (left or right hippocampus) to every voxel of the brain. The SBC map is computed as the Fisher-transformed bivariate correlation coefficients between the ROI BOLD time series and each individual voxel BOLD time series [34]. The mathematical relationship to construct the SBC is:

$$r(x) = \frac{\int S(x,t)R(t)dt}{(\int R^2(t)dt \int S^2(x,t)dt)^{1/2}}$$

$$Z(x) = \tanh^{-1}(r(x))$$

where R is the average ROI BOLD time series in the hippocampus, S is the BOLD time series at each voxel, r is the spatial map of Pearson correlation coefficients, and Z is the SBC map of the Fisher-transformed correlation coefficients for the ROI.

Statistical analysis

IBM SPSS (IBM Corp. Armonk, NY, USA) was used to run independent t -tests on the available

participant data to ensure there was not a statistically significant sex difference in age, the Mini Mental State Examination (MMSE), the Geriatric Depression (GD) Scale, the Global Clinical Dementia Rating (CDR), the Functional Activities Questionnaire (FAQ), and the Neuropsychiatric Inventory Questionnaire (NPI-Q) ($p > 0.05$). If normal distribution could not be assumed based on the Shapiro–Wilk test, a non-parametric Mann–Whitney test was performed.

F -tests were conducted between the SBC maps to compare differences between groups. Female AD participants with at least one $\epsilon 4$ allele SBC maps were compared to Male AD participants with at least one $\epsilon 4$ allele SBC maps. This was repeated for female and male AD participants with no $\epsilon 4$ allele. Additionally, female AD with at least one $\epsilon 4$ allele were compared to females without a $\epsilon 4$ allele, and this was repeated with males. Finally, similar comparisons were made with CN participants. For a cortical area to be considered significant, the toolbox used the Gaussian random field theory parametric statistics, with a cluster threshold $p < 0.05$ (FDR-corrected) and voxel threshold $p < 0.001$ (uncorrected) to control the type I error in multiple comparisons [40]. Due to the small size of the voxel, to reduce differences attributed to noise, the area must be over 100 voxels large or cover more than 80% of a given atlas (specific brain area). These regions of statistical difference

Table 2 Participant demographics (AD, Alzheimer’s disease; CN, cognitively normal; MMSE, Mini Mental State Examination; GD Scale, Geriatric Depression Scale; CDR, Global Clin-

ical Dementia Rating; FAQ, Functional Activities Questionnaire; NPI-Q, Neuropsychiatric Inventory Questionnaire)

Group	Statistic	Age	MMSE	GD Scale	CDR	FAQ	NPI-Q
AD female	$\mu \pm SD$	71.6 \pm 8.6	20.9 \pm 3.9	1.5 \pm 2.1	0.91 \pm 0.20	19.1 \pm 6.3	4.6 \pm 2.9
	% missing	0	26	33	26	26	26
AD male	$\mu \pm SD$	74.5 \pm 5.2	22.3 \pm 2.5	2.0 \pm 1.0	0.91 \pm 0.42	15.8 \pm 7.6	4.5 \pm 4.9
	% missing	0	20	20	20	20	20
AD between sex t -tests		$p=0.267$	$p=0.341$	$p=0.500$	$p=0.956$	$p=0.261$	$p=0.932$
CN female	$\mu \pm SD$	71.5 \pm 4.2	29.47 \pm 0.8	0.93 \pm 1.2	0.04 \pm 0.13	0.0 \pm 0	0.64 \pm 1.4
	% missing	0	0	0	6	6	6
CN male	$\mu \pm SD$	75.9 \pm 6.7	28.2 \pm 2.0	0.6 \pm 0.83	0.07 \pm 0.18	0.33 \pm 1.1	0.73 \pm 1.4
	% missing	0	0	0	0	0	0
CN between sex t -tests		$p=0.060$	$p=0.080$	$p=0.370$	$p=0.600$	$p=0.240$	$p=0.860$




Fig. 1 Seed-based functional connectivity map where functional connectivity differs from zero with the right hippocampus selected as ROI

between SBC maps were then highlighted on a template brain.

Results

Table 1 displays the number of each genotype per group. Table 2 displays participant demographics with statistical analysis to ensure there were no significant sex differences in covariates. The SBC maps for each group with the right hippocampus selected as the ROI are displayed in Fig. 1, this depicts areas of the brain where the functional connectivity differs from zero, with positive in red and negative in blue. Figure 1 demonstrates that there is connectivity within the data before performing statistical analysis between SBC maps.

For each group (female AD, male AD, female CN, and male CN), when the right and left hippocampi were selected as the ROI, the functional connectivity within the right and left hippocampus, respectively, had a significant difference between individuals who have a least one $\epsilon 4$ compared to

those who did not have a $\epsilon 4$ allele with those with no $\epsilon 4$ allele having higher functional connectivity (Table 3). This can be visualized for the right hippocampus ROI in Fig. 2.

With regard to sex in the AD and CN groups, the only difference found was between females and male with AD who have at least one $\epsilon 4$ allele (Table 4). There were no significant sex differences for those with no $\epsilon 4$ allele or between cognitively normal individuals. When the right and left hippocampus were selected as the ROIs (for those with AD that have at least one $\epsilon 4$ allele), the functional connectivity within the right and left hippocampus, respectively, has a significant between-sex group difference with males having higher functional connectivity. This is visualized in Fig. 3. For the right hippocampus ROI, males averaged a connectivity within the right hippocampus of 0.434; the female average was 0.387. For the left hippocampus ROI, males averaged a connectivity within the left hippocampus of 0.543; the female average was 0.353. The functional connectivity values for AD subjects with at least one $\epsilon 4$ allele are provided in Fig. 4.

Table 3 Hippocampal functional connectivity differences between genotypes

Comparison	<i>N</i>	ROI	Brain areas (atlas) of	% atlas covered	# of voxels significant difference
Female (F): Alzheimer's disease (AD) $\epsilon 4$ vs. no $\epsilon 4$	F $\epsilon 4 = 12$	Right hippocampus	Right hippocampus ^a	29%	205
			Left hippocampus	0%	0
Female (FMCI vs. FCN)	F no $\epsilon 4 = 3$	Left hippocampus	Left hippocampus ^a	18%	138
			Right hippocampus	0%	0
Male (M): AD $\epsilon 4$ vs. no $\epsilon 4$	M $\epsilon 4 = 10$	Right hippocampus	Right hippocampus ^a	25%	172
			Left hippocampus	3%	22
	M no $\epsilon 4 = 5$	Left hippocampus	Left hippocampus ^a	22%	168
			Right hippocampus	3%	20
F: cognitively normal (CN) $\epsilon 4$ vs. no $\epsilon 4$	F $\epsilon 4 = 7$	Right hippocampus	Right hippocampus ^a	17%	122
			Left hippocampus	0%	0
Female (FMCI vs. FCN)	F no $\epsilon 4 = 8$	Left hippocampus	Left hippocampus ^a	28%	215
			Right hippocampus	0%	0
M: CN $\epsilon 4$ vs. no $\epsilon 4$	M $\epsilon 4 = 5$	Right hippocampus	Right hippocampus ^a	19%	131
			Left hippocampus	1%	10
	M no $\epsilon 4 = 10$	Left hippocampus	Left hippocampus ^a	18%	140
			Right hippocampus	2%	12

^aThe area is large enough to be statistically significant




Fig. 2 Hippocampal functional connectivity difference between individuals with an $\epsilon 4$ allele versus those without $\epsilon 4$ allele with right hippocampus as ROI. Highlighted display the statistically significant cortical regions ($p < 0.001$)

Discussion

This study supports that there are sex differences in cortical pathophysiological biomarkers in AD. Specifically, this research expands the current understanding of intrahippocampal communication,

demonstrating that the ApoE $\epsilon 4$ allele may play a role in the observed sex differences in hippocampal functional connectivity in AD.

Our finding that resting-state FC differs between those with an $\epsilon 4$ allele versus those without an $\epsilon 4$ allele is consistent with previous research. Several

Table 4 Hippocampal functional connectivity differences between sexes

Comparison	N	ROI	Brain areas (atlas) of significant difference	% atlas covered	# of voxels
Alzheimer's disease (AD) ϵ 4: female (F) vs. male (M) (FMCI vs. FCN)	F=12	Right hippocampus	Right hippocampus ^a	33%	228
			Left hippocampus	0%	0
	M=10	Left hippocampus	Left hippocampus ^a	39%	250
AD ϵ 3: F vs. M	F=3	Right hippocampus	Right hippocampus	1%	5
			Left hippocampus	0%	0
	M=5	Left hippocampus	Left hippocampus	1%	3
			Right hippocampus	0%	0
			Right hippocampus	0%	0
Cognitively normal (CN) ϵ 4: F vs. M (FMCI vs. FCN)	F=7	Right hippocampus	Right hippocampus	2%	11
			Left hippocampus	0%	0
	M=5	Left hippocampus	Left hippocampus	3%	30
			Right hippocampus	1%	4
CN ϵ 3: F vs. M	F=8	Right hippocampus	Right hippocampus	5%	38
			Left hippocampus	0%	0
	M=10	Left hippocampus	Left hippocampus	6%	48
			Right hippocampus	0%	0

^aThe area is large enough to be statistically significant

studies have reported that the ApoE ϵ 4 allele is associated with decreased FC in cognitively normal adults as well as in mouse models [41–45]. In AD, the ApoE ϵ 4 allele is shown to change both structural and functional characteristics, specifically within the hippocampus [46, 47]. It is also known that intrahippocampal functional hippocampal connectivity is decreased in Alzheimer's compared to controls [48, 49]. This has also been demonstrated in 3xTg mouse models [48]. This difference may be a direct decrease, or there may also be in compensatory pathways of the hippocampus. Research has shown that there is a generation of maladaptive compensatory mechanisms associated with AD [50, 51]. Further, this difference in hippocampal communication may also differ between females and males with AD [28, 29]. However, the novel finding of this research is the possibility that this sex difference may be linked to an interacting genetic factor, ApoE.

The sex difference in hippocampal FC was only observed between participants that had AD and had at least one ApoE ϵ 4 allele. Comprehensive studies

have shown that ApoE ϵ 4 carriers have atrophic hippocampal volumes and that the sex modulates the ApoE-related decrease in both gray and white matter activity [52, 53]. However, how ApoE is related to the difference in hippocampal FC between males and females remains unknown. ApoE ϵ 4 has been shown to modulate neurodegeneration in a sex-specific manner, with females having a stronger association between ApoE and tau levels and amyloid- β , particularly in the presence of amyloidosis [54, 55]. Therefore, one hypothesis may be that ApoE affects tau protein aggregates or amyloidogenic processes differently, which is then playing a role in disconnecting the hippocampus from specific memory systems resulting in worse neuropsychological task performance seen in females [8, 56]. Another hypothesis is related to the female endocrine and reproductive history. It could be that the observed sex differences in functional connectivity are the result of the activation effects of cycling hormones in women prior to menopause. It is known that across the menstrual cycle, there is gray matter plasticity in the hippocampal, the amygdala, and the




Fig. 3 Hippocampal functional connectivity difference between females and males with AD who have an $\epsilon 4$ allele. Highlighted display the statistically significant cortical regions ($p < 0.001$)

temporal and parietal regions of the brain [57]. One could observe if functional connectivity in women who had hysterectomies or hormone therapy is more similar or different from men.

Further, there are other biological and gender considerations regarding ApoE and aging. The ApoE $\epsilon 4$ allele has been shown to have a large impact on stress response–related processes, including a strong interconnection between mitochondrial function, endoplasmic reticulum stress, synaptic integrity, and the immune response [58, 59]. In addition to AD, the ApoE genotype is related to the severity of other proteinopathies and neurodegenerative diseases characterized by overt neuroinflammation [60]. These include multiple

sclerosis, Parkinson’s, dementia with Lewy bodies, and amyotrophic lateral sclerosis. These conditions also have reported sex differences in both development and progression [61]. The study of sex differences in these different neurological conditions, including AD, is significant as it could lead to an understanding of the molecular underpinning of ApoE and further the advancement of precise treatment based on sex.

It should be noted that the sample size of this study was small, and the cross-sectional design further constrains conclusions about the nature of change in hippocampal activity over time. Future work should include longitudinal designs to track these changes in larger samples to provide more




Fig. 4 Functional connectivity of right hippocampus ROI to the right hippocampus and left hippocampus ROI to the left hippocampus in AD participants with at least one $\epsilon 4$ allele

robust statistical power and a more representative spectrum of the AD population. The sample size (that was limited by fMRIs available on the ADNI database) also did not allow for separating the genotypes further, for example, observing the differences between homozygous and heterozygous ApoE $\epsilon 4$ carriers or exploring the differences that may emerge with ApoE $\epsilon 2$. Further, our analysis included the uneven distribution of heterozygotes and homozygotes across sexes, most significantly within the AD group with at least one ApoE $\epsilon 4$ allele. With an increased number of participants, the number in each group would be equalized to ensure this is not a confounding variable. With an increased number of participants to allow for larger groups, this future work would strengthen the study of sex, ApoE, and functional connectivity of the hippocampus. Additionally, exploring the molecular

underpinning of ApoE including a study with tau or amyloid- β levels would provide an indication of their role in changes to connectivity. Another important future work would be focusing on the effects of the female reproductive cycle. Nevertheless, the current finding supports accounting for sex and ApoE genotype in neuroimaging biomarkers, diagnostics, and treatments. Additionally, it furthers the rationale for the development of sex-specific interventions using the emerging cortical pathophysiological biomarkers, such as non-invasive brain stimulation (NIBS) to optimize therapeutic outcomes [62, 63]. The prospect of sex-specific interventions also calls for a deeper examination of the socio-cultural dimensions of AD. Gender roles and environmental factors may exacerbate or mitigate expressions of genetic risk, which warrants consideration in research and clinical settings.

Acknowledgements Alzheimer's disease neuroimaging initiative investigators:

Michael Weiner⁹, Paul Aisen¹⁰, Ronald Petersen¹¹, Clifford R. Jack Jr¹¹, William Jagust¹², John Q. Trojanowski¹³, Arthur W. Toga¹⁴, Laurel Beckett¹⁵, Robert C. Green¹⁶, Andrew J. Saykin¹⁷, John C. Morris²⁷, Leslie M. Shaw¹³, Enchi Liu¹⁸, Tom Montine¹⁹, Ronald G. Thomas¹⁰, Michael Donohue¹⁰, Sarah Walter¹⁰, Devon Gessert¹⁰, Tamie Sather¹⁰, Gus Jimenez¹⁰, Danielle Harvey¹⁵, Matthew Bernstein¹⁰, Nick Fox²⁰, Paul Thompson²¹, Norbert Schuff²², Charles DeCarli¹⁵, Bret Borowski¹¹, Jeff Gunter¹¹, Matt Senjem¹¹, Prashanthi Vemuri¹¹, David Jones¹¹, Kejal Kantarci¹¹, Chad Ward¹¹, Robert A. Koeppe²³, Norm Foster²⁴, Eric M. Reiman²⁵, Kewei Chen²⁵, Chet Mathis²⁶, Susan Landau¹², Nigel J. Cairns²⁷, Erin Householder¹⁴, Lisa Taylor Reinwald²⁷, Virginia Lee²⁸, Magdalena Korecka²⁸, Michal Figurski²⁸, Karen Crawford¹⁴, Scott Neu¹⁴, Tatiana M. Foroud¹⁷, Steven Potkin²⁹, Li Shen¹⁷, Faber Kelley¹⁷, Sungeun Kim¹⁷, Kwangsik Nho¹⁷, Zaven Kachaturian³⁰, Richard Frank³¹, Peter J. Snyder³², Susan Molchan³³, Jeffrey Kaye³⁴, Joseph Quinn³⁴, Betty Lind³⁴, Raina Carter³⁴, Sara Dolen³⁴, Lon S. Schneider¹⁴, Sonia Pawluczyk¹⁴, Mauricio Beccera¹⁴, Liberty Teodoro¹⁴, Bryan M. Spann¹⁴, James Brewer¹⁰, Helen Vanderswag¹⁰, Adam Fleisher¹⁰, Judith L. Heidebrink²³, Joanne L. Lord²³, Ronald Petersen¹¹, Sara S. Mason¹¹, Colleen S. Albers¹¹, David Knopman¹¹, Kris Johnson¹¹, Rachelle S. Doody³⁵, Javier Villanueva Meyer³⁵, Munir Chowdhury³⁵, Susan Rountree³⁵, Mimi Dang³⁵, Yaakov Stern³⁶, Lawrence S. Honig³⁶, Karen L. Bell³⁶, Beau Ances²⁷, Maria Carroll²⁷, Sue Leon²⁷, Erin Householder²⁷, Mark A. Mintun²⁷, Stacy Schneider²⁷, Angela OliverNG³⁷, Randall Griffith³⁷, David Clark³⁷, David Geldmacher³⁷, John Brockington³⁷, Erik Roberson³⁷, Hillel Grossman³⁸, Effie Mitsis³⁸, Leyla deToledo-Morrell³⁹, Raj C. Shah³⁹, Ranjan Duara⁴⁰, Daniel Varon⁴⁰, Maria T. Greig⁴⁰, Peggy Roberts⁴⁰, Marilyn Alber⁴¹, Chiadi Onyike⁴¹, Daniel D'Agostino II⁴¹, Stephanie Kielb⁴¹, James E. Galvin⁴², Dana M. Pogorele⁴², Brittany Carbone⁴², Christina A. Michel⁴², Henry Rusinek⁴², Momy J. de Leon⁴², Lidia Glodzik⁴², Susan De Santi⁴², P. Murali Doraiswamy⁴³, Jeffrey R. Petrella⁴³, Terence Z. Wong⁴³, Steven E. Arnold¹³, Jason H. Karlawish¹³, David A. Wolk²⁶, Charles D. Smith⁴⁴, Greg Jicha⁴⁴, Peter Hardy⁴⁴, Partha Sinha⁴⁴, Elizabeth Oates⁴⁴, Gary Conrad⁴⁴, Oscar L. Lopez²⁶, MaryAnn Oakley²⁶, Donna M. Simpson²⁶, Anton P. Porsteinsson⁴⁵, Bonnie S. Goldstein⁴⁵, Kim Martin⁴⁵, Kelly M. Makino⁴⁵, M. Saleem Ismail⁴⁵, Connie Brand⁴⁵, Ruth A. Mulnard²⁹, Gaby Thai²⁹, Catherine Mc Adams Ortiz²⁹, Kyle Womack⁴⁶, Dana Mathews⁴⁶, Mary Quiceno⁴⁶, Ramon Diaz Arrastia⁴⁶, Richard King⁴⁶, Myron Weiner⁴⁶, Kristen Martin Cook⁴⁶, Michael DeVous⁴⁶, Allan I. Levey⁴⁷, James J. Lah⁴⁷, Janet S. Cellar⁴⁷, Jeffrey M. Burns⁴⁸, Heather S. Anderson⁴⁸, Russell H. Swerdlow⁴⁸, Liana Apostolova⁴⁹, Kathleen Tingus⁴⁹, Ellen Woo⁴⁹, Daniel H. S. Silverman⁴⁹, Po H. Lu⁴⁹, George Bartzokis⁴⁹, Neill R. Graff Radford⁵⁰, Francine Parfitt⁵⁰, Tracy Kendall⁵⁰, Heather Johnson⁵⁰, Martin R. Farlow¹⁷, Ann Marie Hake¹⁷, Brandy R. Matthews¹⁷, Scott Herring¹⁷, Cynthia Hunt¹⁷, Christopher H. van Dyck⁵¹, Richard E. Carson⁵¹, Martha G. MacAvoy⁵¹, Howard Chertkow⁵², Howard Bergman⁵², Chris Hosein⁵², Sandra Black⁵³, Bojana Stefanovic⁵³, Curtis Caldwell⁵³, Ging Yuek Robin Hsiung⁵⁴, Howard Feldman⁵⁴, Benita Mudge⁵⁴, Michele Assaly Past⁵⁴, Andrew Kertesz⁵⁵, John Rogers⁵⁵, Dick Trost⁵⁵, Charles Bernick⁵⁶, Donna

Munic⁵⁶, Diana Kerwin⁵⁷, Marek Marsel Mesulam⁵⁷, Kristine Lipowski⁵⁷, Chuang Kuo Wu⁵⁷, Nancy Johnson⁵⁷, Carl Sadowsky⁵⁸, Walter Martinez⁵⁸, Teresa Villena⁵⁸, Raymond Scott Turner⁵⁹, Kathleen Johnson⁵⁹, Brigid Reynolds⁵⁹, Reisa A. Sperling¹⁶, Keith A. Johnson¹⁶, Gad Marshall¹⁶, Meghan Frey¹⁶, Jerome Yesavage⁶⁰, Joy L. Taylor⁶⁰, Barton Lane⁶⁰, Allyson Rosen⁶⁰, Jared Tinklenberg⁶⁰, Marwan N. Sabbagh⁶¹, Christine M. Belden⁶¹, Sandra A. Jacobson⁶¹, Sherye A. Sirrel⁶¹, Neil Kowall⁶², Ronald Killiany⁶², Andrew E. Budson⁶², Alexander Norbash⁶², Patricia Lynn Johnson⁶², Thomas O. Obisesan⁶³, Saba Wolday⁶³, Joanne Allard⁶³, Alan Lerner⁶⁴, Paula Ogrocki⁶⁴, Leon Hudson⁶⁴, Evan Fletcher⁶⁵, Owen Carmichael⁶⁵, John Olichney⁶⁵, Charles DeCarli⁶⁵, Smita Kittur⁶⁶, Michael Borrie⁶⁷, T. Y. Lee⁶⁷, Rob Bartha⁶⁷, Sterling Johnson⁶⁸, Sanjay Asthana⁶⁸, Cynthia M. Carlsson⁶⁸, Steven G. Potkin⁶⁹, Adrian Preda⁶⁹, Dana Nguyen⁶⁹, Pierre Tariot²⁵, Adam Fleisher²⁵, Stephanie Reeder²⁵, Vernice Bates⁷⁰, Horacio Capote⁷⁰, Michelle Rainka⁷⁰, Douglas W. Scharre⁷¹, Maria Katakai⁷¹, Anahita Adeli⁷¹, Earl A. Zimmerman⁷², Dzintra Celmins⁷², Alice D. Brown⁷², Godfrey D. Pearlson⁷³, Karen Blank⁷³, Karen Anderson⁷³, Robert B. Santulli⁷⁴, Tamar J. Kitzmiller⁷⁴, Eben S. Schwartz⁷⁴, Kaycee M. Sink⁷⁵, Jeff D. Williamson⁷⁵, Pradeep Garg⁷⁵, Franklin Watkins⁷⁵, Brian R. Ott⁷⁶, Henry Querfurth⁷⁶, Geoffrey Tremont⁷⁶, Stephen Salloway⁷⁷, Paul Malloy⁷⁷, Stephen Correia⁷⁷, Howard J. Rosen⁹, Bruce L. Miller⁹, Jacobo Mintzer⁷⁸, Kenneth Spicer⁷⁸, David Bachman⁷⁸, Elizabeth Finger⁷⁹, Stephen Pasternak⁷⁹, Irina Rachinsky⁷⁹, John Rogers⁷⁹, Andrew Kertesz⁷⁹, Dick Drost⁷⁹, Nunzio Pomara⁸⁰, Raymundo Hernandez⁸⁰, Antero Sarraeal⁸⁰, Susan K. Schultz⁸¹, Laura L. Boles Ponto⁸¹, Hyung-sub Shim⁸¹, Karen Elizabeth Smith⁸¹, Norman Relkin⁸², Gloria Chaing⁸², Lisa Raudin⁸², Amanda Smith⁸³, Kristin Fargher⁸³ & Balebail Ashok Raj⁸³

⁹UC San Francisco, San Francisco, CA, USA. ¹⁰University of California San Diego, San Diego, CA, USA. ¹¹Mayo Clinic, Rochester, NY, USA. ¹²UC Berkeley, Berkeley, CA, USA. ¹³University of Pennsylvania, Philadelphia, PA, USA. ¹⁴University of Southern California, Los Angeles, CA, USA. ¹⁵Davis, Davis, CA, USA. ¹⁶Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. ¹⁷Indiana University, Bloomington, IND, USA. ¹⁸Janssen Alzheimer Immunotherapy, South San Francisco, CA, USA. ¹⁹University of Washington, Seattle, WA, USA. ²⁰University of London, London, UK. ²¹USC School of Medicine, Los Angeles, CA, USA. ²²UCSF MRI, San Francisco, CA, USA. ²³University of Michigan, Ann Arbor, MI, USA. ²⁴University of Utah, Salt Lake City, UT, USA. ²⁵Banner Alzheimer's Institute, Phoenix, AZ, USA. ²⁶University of Pittsburgh, Pittsburgh, PA, USA. ²⁷Washington University St. Louis, St. Louis, MO, USA. ²⁸UPenn School of Medicine, Philadelphia, PA, USA. ²⁹University of California, Irvine, CA, USA. ³⁰Kachaturian, Radebaugh & Associates, Inc and Alzheimer's Association's Ronald and Nancy Reagan's Research Institute, Chicago, IL, USA. ³¹General Electric, Boston, MA, USA. ³²Brown University, Providence, RI, USA. ³³National Institute on Aging/National Institutes of Health, Bethesda, MD, USA. ³⁴Oregon Health and Science University, Portland, OR, USA. ³⁵Baylor College of Medicine, Houston, TX, USA. ³⁶Columbia University Medical Center, New York, NY, USA. ³⁷University of Alabama Birmingham, Birmingham, MO, USA. ³⁸Mount Sinai School of Medicine, New York, NY, USA. ³⁹Rush University Medical Center, Chicago, IL, USA. ⁴⁰Wien Center, Vienna, Austria.

⁴¹Johns Hopkins University, Baltimore, MD, USA. ⁴²New York University, New York, NY, USA. ⁴³Duke University Medical Center, Durham, NC, USA. ⁴⁴University of Kentucky, Lexington, KY, USA. ⁴⁵University of Rochester Medical Center, Rochester, NY, USA. ⁴⁶University of Texas Southwestern Medical School, Dallas, TX, USA. ⁴⁷Emory University, Atlanta, GA, USA. ⁴⁸University of Kansas, Medical Center, Lawrence, KS, USA. ⁴⁹University of California, Los Angeles, CA USA. ⁵⁰Mayo Clinic, Jacksonville, FL, USA. ⁵¹Yale University School of Medicine, New Haven, CT, USA. ⁵²McGill Univ., Montreal Jewish General Hospital, Montreal, WI, USA. ⁵³Sunnybrook Health Sciences, Toronto, ON, Canada. ⁵⁴U.B.C. Clinic for AD & Related Disorders, British Columbia, BC, Canada. ⁵⁵Cognitive Neurology St. Joseph's, Toronto, ON, Canada. ⁵⁶Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA. ⁵⁷Northwestern University, Evanston, IL, USA. ⁵⁸Premiere Research Inst Palm Beach Neurology, West Palm Beach, FL, USA. ⁵⁹Georgetown University Medical Center, Washington, DC, USA. ⁶⁰Stanford University, Santa Clara County, CA, USA. ⁶¹Banner Sun Health Research Institute, Sun City, AZ, USA. ⁶²Boston University, Boston, MA, USA. ⁶³Howard University, Washington, DC, USA. ⁶⁴Case Western Reserve University, Cleveland, OH, USA. ⁶⁵University of California, Davis Sacramento, CA, USA. ⁶⁶Neurological Care of CNY, New York, NY, USA. ⁶⁷Parkwood Hospital, Parkwood, CA, USA. ⁶⁸University of Wisconsin, Madison, WI, USA. ⁶⁹University of California, Irvine BIC, Irvine, CA, USA. ⁷⁰Dent Neurologic Institute, Amherst, MA, USA. ⁷¹Ohio State University, Columbus, OH, USA. ⁷²Albany Medical College, Albany, NY, USA. ⁷³Hartford Hosp. Olin Neuropsychiatry Research Center, Hartford, CT, USA. ⁷⁴Dartmouth Hitchcock Medical Center, Albany, NY, USA. ⁷⁵Wake Forest University Health Sciences, Winston-Salem, NC, USA. ⁷⁶Rhode Island Hospital, Providence, RI, USA. ⁷⁷Butler Hospital, Providence, RI, USA. ⁷⁸Medical University South Carolina, Charleston, SC, USA. ⁷⁹St. Joseph's Health Care, Toronto, ON, Canada. ⁸⁰Nathan Kline Institute, Orangeburg, SC, USA. ⁸¹University of Iowa College of Medicine, Iowa City, IA, USA. ⁸²Cornell University, Ithaca, NY, USA. ⁸³University of South Florida: USF Health Byrd Alzheimer's Institute, Tampa, FL, USA.

Author contribution J.W. conducted the study and drafted the manuscript. Y.Y. contributed to conceptualization, problem-solving, and guidance during the conduction of the study. S.J., S.M., B.S., T.W., P.M., A.Y., and Y.Y. participated in editing the manuscript.

Funding Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development,

LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. This work was also partially supported by the American Heart Association (AHA834339) and the National Institute on Aging of National Institutes of Health (R01AG075834) awards. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Data availability All data derived from the ADNI and that specific to this study are available to researchers by request as outlined in the ADNI access policy (adni.loni.usc.edu).

Declarations

Ethics approval and consent to participate The Institutional Review Boards of all participating ADNI sites reviewed and approved the data collection protocols provided by ADNI.

Consent for publication Not applicable.

Competing interests The authors declare no competing interests.

References

1. Alzheimer's Association. 2023 Alzheimer's disease facts and figures. *Alzheimers Dement.* 2023;19(4):1598–95.
2. National Institute of Health. Alzheimer's disease. 2021. Available from <https://www.nih.gov/research-training/accelerating-medicines-partnership-amp/alzheimers-disease>. Accessed 30 Jan 2023.
3. Alzheimer's Association. 2022 Alzheimer's disease facts and figures. *Alzheimers Dement.* 2022;18(4):700–89.
4. National Institute on Aging. What happens to the brain in Alzheimer's disease? National Institute on Aging; 2017.
5. Guo T, et al. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. *Mol Neurodegener.* 2020;15(1):1–37.
6. Chapman RM, et al. Women have farther to fall: gender differences between normal elderly and Alzheimer's disease in verbal memory engender better detection of Alzheimer's disease in women. *J Int Neuropsychol Soc.* 2011;17(4):654–62.

7. Gumus M, et al. Progression of neuropsychiatric symptoms in young-onset versus late-onset Alzheimer's disease. *Geroscience*. 2021;43:213–23.
8. Henderson VW, Buckwalter JG. Cognitive deficits of men and women with Alzheimer's disease. *Neurology*. 1994;44(1):90–6.
9. Andrew MK, Tierney MC. The puzzle of sex, gender and Alzheimer's disease: why are women more often affected than men? *Womens Health*. 2018;14:1745506518817995.
10. Mielke MM. Sex and gender differences in Alzheimer's disease dementia. *Psychiatr Times*. 2018;35(11):14–7.
11. Mielke MM, et al. Consideration of sex and gender in Alzheimer's disease and related disorders from a global perspective. *Alzheimers Dement*. 2022;18(12):2707–24.
12. Pearce EE, et al. Telomere length and epigenetic clocks as markers of cellular aging: a comparative study. *Geroscience*. 2022;44(3):1861–9.
13. Guerreiro R, Bras J. The age factor in Alzheimer's disease. *Genome Med*. 2015;7(1):1–3.
14. Li Z, et al. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. *Mol Neurodegener*. 2020;15(1):63.
15. Sando SB, et al. APOE ϵ 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. *BMC Neurol*. 2008;8:1–7.
16. Yamazaki Y, et al. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nat Rev Neurol*. 2019;15(9):501–18.
17. Michaelson DM. APOE ϵ 4: the most prevalent yet understudied risk factor for Alzheimer's disease. *Alzheimers Dement*. 2014;10(6):861–8.
18. Liu C-C, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. *Nat Rev Neurol*. 2013;9(2):106–18.
19. Emrani S, et al. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer's disease: a systematic review. *Alzheimers Res Ther*. 2020;12(1):141.
20. Sienski G, et al. APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia. *Sci Transl Med*. 2021;13(583):eaaz4564.
21. Canuet L, et al. Resting-state network disruption and APOE genotype in Alzheimer's disease: a lagged functional connectivity study. *PLoS ONE*. 2012;7(9): e46289.
22. Jelic V, et al. Apolipoprotein E ϵ 4 allele decreases functional connectivity in Alzheimer's disease as measured by EEG coherence. *J Neurol Neurosurg Psychiatry*. 1997;63(1):59–65.
23. Adluru N, et al. Sex differences of APOE neuropathology-based scores in brain aging. *Alzheimers Dement*. 2023;19: e064003.
24. Neu SC, et al. Apolipoprotein E genotype and sex risk factors for alzheimer disease: a meta-analysis. *JAMA Neurol*. 2017;74(10):1178–89.
25. Sundermann EE, et al. Sex differences in the association between apolipoprotein E ϵ 4 allele and Alzheimer's disease markers. *Alzheimers Dementia Diagn Assess Dis Monit*. 2018;10:438–47.
26. Burke SL, et al. Sex differences in the development of mild cognitive impairment and probable Alzheimer's disease as predicted by hippocampal volume or white matter hyperintensities. *J Women Aging*. 2019;31(2):140–64.
27. Ardekani BA, Convit A, Bachman AH. Analysis of the MIRIAD data shows sex differences in hippocampal atrophy progression. *J Alzheimers Dis*. 2016;50:847–57.
28. Deuschendorf L. Gender differences in the functional connectivity of the hippocampus in Alzheimer's disease. 2023, Dissertation, Tilburg University.
29. Williamson J, et al. Sex difference in brain functional connectivity of hippocampus in Alzheimer's disease. *GeroScience*. 2024;46(1):563–72.
30. Williamson J, et al. Sex differences in brain functional connectivity of hippocampus in mild cognitive impairment. *Frontiers in Aging Neuroscience*. 2022;14: 959394.
31. Cavedo E, et al. Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. *Alzheimers Dement*. 2018;14(9):1204–15.
32. Heise V, et al. Apolipoprotein E genotype, gender and age modulate connectivity of the hippocampus in healthy adults. *Neuroimage*. 2014;98:23–30.
33. Weiner MW. Alzheimer's disease neuroimaging initiative. Available from <https://adni.loni.usc.edu/>. Accessed 30 Jan 2023.
34. Whitfield-Gabriel S, Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. *Brain Connect*. 2012;2(3):125–41.
35. Jenkinson M, et al. Fsl. *Neuroimage*. 2012;62(2):782–90.
36. Smith SM, et al. Advances in functional and structural MR image analysis and implementation as FSL. *Neuroimage*. 2004;23:S208–19.
37. Woolrich MW, et al. Bayesian analysis of neuroimaging data in FSL. *Neuroimage*. 2009;45(1 Suppl):S173–86.
38. Tzourio-Mazoyer N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*. 2002;15(1):273–89.
39. Nieto-Castanon A. Handbook of functional connectivity magnetic resonance imaging methods in CONN. Boston, MA: Hilbert Press; 2020.
40. Worsley KJ, et al. A unified statistical approach for determining significant signals in images of cerebral activation. *Hum Brain Mapp*. 1996;4(1):58–73.
41. Chen Y, et al. Disrupted functional and structural networks in cognitively normal elderly subjects with the APOE ϵ 4 allele. *Neuropsychopharmacology*. 2015;40(5):1181–91.
42. Fleisher AS, et al. Resting-state BOLD networks versus task-associated functional MRI for distinguishing Alzheimer's disease risk groups. *Neuroimage*. 2009;47(4):1678–90.
43. Matura S, et al. Recognition memory is associated with altered resting-state functional connectivity in people at genetic risk for Alzheimer's disease. *Eur J Neurosci*. 2014;40(7):3128–35.
44. Turney IC, et al. APOE ϵ 4 and resting-state functional connectivity in racially/ethnically diverse older adults. *Alzheimers Dementia Diagn Assess Dis Monit*. 2020;12(1): e12094.
45. Zerbi V, et al. Resting-state functional connectivity changes in aging apoE4 and apoE-KO mice. *J Neurosci*. 2014;34(42):13963–75.

46. Shen J, et al. Modulation of APOE and SORL1 genes on hippocampal functional connectivity in healthy young adults. *Brain Struct Funct*. 2017;222(6):2877–89.
47. Wang X, et al. Apolipoprotein E ϵ 4 modulates cognitive profiles, hippocampal volume, and resting-state functional connectivity in Alzheimer's disease. *J Alzheimers Dis*. 2015;45:781–95.
48. Manno FA, et al. Early stage alterations in white matter and decreased functional interhemispheric hippocampal connectivity in the 3xTg mouse model of Alzheimer's disease. *Front Aging Neurosci*. 2019;11:39.
49. Wang Z, et al. Interhemispheric functional and structural disconnection in Alzheimer's disease: a combined resting-state fMRI and DTI study. *PLoS ONE*. 2015;10(5):e0126310.
50. Aganj I, et al. Compensatory brain connection discovery in Alzheimer's disease. *Proc IEEE Int Symp Biomed Imaging*. 2020;2020:283–7.
51. Gardini S, et al. Increased functional connectivity in the default mode network in mild cognitive impairment: a maladaptive compensatory mechanism associated with poor semantic memory performance. *J Alzheimers Dis*. 2015;45:457–70.
52. Liu Y, et al. APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis. *J Neurol Neurosurg Psychiatry*. 2015;86(2):127–34.
53. Lin H, et al. Sex modulates the apolipoprotein E ϵ 4 effect on white matter and cortical functional connectivity in individuals with amnesic mild cognitive impairment. *Eur J Neurol*. 2020;27(8):1415–21.
54. Hohman TJ, et al. Sex-specific association of apolipoprotein E with cerebrospinal fluid levels of tau. *JAMA Neurol*. 2018;75(8):989–98.
55. Nyarko JNK, et al. Profiles of β -amyloid peptides and key secretases in brain autopsy samples differ with sex and APOE ϵ 4 status: impact for risk and progression of Alzheimer disease. *Neuroscience*. 2018;373:20–36.
56. Harrison TM, et al. Tau deposition is associated with functional isolation of the hippocampus in aging. *Nat Commun*. 2019;10(1):4900.
57. Rehbein E, et al. Shaping of the female human brain by sex hormones: a review. *Neuroendocrinology*. 2021;111(3):183–206.
58. Dose J, et al. APOE genotype and stress response - a mini review. *Lipids Health Dis*. 2016;15(1):121.
59. Yin J, et al. Effect of ApoE isoforms on mitochondria in Alzheimer disease. *Neurology*. 2020;94(23):e2404–11.
60. Robinson JL, et al. Neurodegenerative disease comorbid proteinopathies are prevalent, age-related and APOE4-associated. *Brain*. 2018;141(7):2181–93.
61. Gamache J, Yun Y, Chiba-Falek O. Sex-dependent effect of APOE on Alzheimer's disease and other age-related neurodegenerative disorders. *Dis Model Mech*. 2020;13(8):211.
62. Casula EP, et al. Regional precuneus cortical hyperexcitability in Alzheimer's disease patients. *Ann Neurol*. 2023;93(2):371–83.
63. Koch G, et al. Transcranial magnetic stimulation of the precuneus enhances memory and neural activity in prodromal Alzheimer's disease. *Neuroimage*. 2018;169:302–11.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.